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• Radiation therapy is used independently or 
in combination with other oncology 
modalities to treat or relieve symptoms of 
cancer patients. High-intensity radiation 
interacts with the tumor while sparing 
healthy tissue. 
• Depending on tumor location, life 
expectancy, and severity of symptoms, the 
oncology team must coordinate this 
information into treatment planning. 
• Those with terminal cancer have 
decreasing end-of-life qualities. The goal of 
radiation therapy then becomes symptom 
relief rather than cancer treatment and 
survival. (Bussman-Yeakel, 2016, p. 480)
Introduction
• Palliative radiotherapy practices are widely utilized in 
30-40% of all cancer treatments (Huynh & Spektor, 
2019, p. 326)
• Quality of life can be increased with the proper use 
of palliative radiotherapy
• If used properly, can achieve:
• Decreased symptoms
• Decreased hospitalizations 
• A preferred environment at the time of 
death
• Avoiding end-of-life chemotherapy 
treatments
• Access to strong opioids 
• Those who receive palliative 
radiotherapy are 2x more 
likely to have access than 
those who refuse palliative 
radiotherapy (Ziegler et al., 
2017, p. 7).
What is Palliative Radiotherapy?
• Performance status (PS) has been found to be the 
“predominant prognostic factor and a significant 
predictor for futile radiotherapy at the end of life” 
(Støchkel Frank et al., 2018, p. 2)
• Those with better performance status 
results in longer survival after treatment 
when given fractionalized palliative 
radiotherapy compared to those with 
worse performance status. 
• Palliative radiotherapy may be futile in types of 
cancer that only show symptoms in a later stage. This 
causes the diagnosis to be delayed, thus pushing off 
appropriate treatment. 
• This includes metastasized cancers with 
multiple lesions throughout the body.
• The microenvironments of the cancer site must be 
considered when planning.
o In lower dose palliative radiotherapy, there is 
preserved vasculature which allows the tumor to 
start reconstructing to normal tissue characteristics. 
In higher doses, there is overall tumor ablation 
which results in programmed vasculature cell 
death.
• Fibroblastic microenvironments 
require a higher dose per fraction to 
speed up the radiation response. 
(Huynh & Spektor, 2019, pp. 328-329)
Determining a Guideline
• Studies have found that the “association between 
longer interval[s] from first contact with palliative 
care to death” results in increased end-of-life 
qualities (Ziegler et al., 2018, p.8)
• If palliative care is not administered 
until the last four weeks of life, it will 
not be as effective compared to those 
who have undergone palliative 
radiotherapy for a longer period 
(Ziegler et al, 2018, p. 8)
• The earlier the stage at diagnosis, the 
sooner palliative radiotherapy can be 
deemed necessary and administered.
• A treatment’s effects with more dose per fraction 
for less fractions are found to be relieved two 
weeks quicker than a treatment with less dose per 
fraction for more fractions (Støchkel Frank et al., 
2018, p. 6)
• This results in relief of symptoms with 
high dose and low toxicity. 
The Key: Timing and Fractioniation
• Palliative radiotherapy is only effective when 
planned and administered appropriately. It is 
important for the radiation therapy team to have a 
dialogue about treatment plans for each individual 
patient. Those with advanced cancer and 
developed symptoms need higher doses at less 
fractions to feel quicker relief than those with less 
severe symptoms for the same type of cancer. 
• It is important to assess PS when determining the 
prescription. The timing of palliative radiotherapy 
is crucial for positive effects to occur in the 
patient. Palliative radiotherapy is futile with near 
end-of-life prognoses because of delayed 
treatment. Instead, these patients should be 
given supportive care or hospice services (Puckett, 
Luitweiler, Potters, & Teckie, 2017, p. 788).
Conclusion
Cancer Severity
• Graph showing the correlation between time from 
prescription of palliative radiotherapy to death with 
chance of survival. 
• Colored lines represent the PS of patients undergoing 
palliative radiotherapy. The difference between PS 2 and 
PS 3-4 was not statistically significant. Those with a PS 
of 2 or more were found to have less time of survival 
throughout treatment compared to those with better PS. 
This graph shows that when diagnosis and palliative 
treatment is delayed, action becomes futile and there is 
no benefit against terminal cancer effects.
(Støchkel Frank et al., 2018)
In the Future
• Few studies have been conducted to evaluate 
how to maximize effectiveness of palliative 
radiotherapy. 
• Multiple articles have found that 
earlier and proper diagnosis by 
physicians is crucial. 
• Advanced technologies are being used to further 
assess prognosis. The use of biomarkers is a 
non-invasive way to determine biological changes 
(responsiveness) throughout treatment as well as 
tumor relapse. (Huynh & Spektor, 2019, p. 332)
Images show a single-fraction treatment plan for a breast 
cancer patient with bone metastases. Picture B & D can be 
compared to show the response after treatment.
(Loi, Nuyttens, Desideri, Greto, & Livi, 2019)
Image of a linear accelerator used for patients with 
external beam radiation therapy treatments (Bussman-
Yeakel, 2016)
Stage 0 Abnormal cells begin to 
form but are not or 
minimally detected.
Stage 1 Localized tumor with no 
additional spread.
Stage 2 Tumor has grown to a 
size less than 5 cm. 
Lymph nodes start to 
become effected.
Stage 3 Tumor has grown to a 
size larger than 5 cm. 
Spreads into deeper 
structures. 
Stage 4 Cancer has 
metastasized to other 
areas of the body.
(Bussman-Yeakel, 2016, p. 483)
